Is Elicio Therapeutics, Inc. (ELTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 13.0% / 30% | 8.8% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 13.0% / 33% | 8.8% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 92.4% / 33% | 62.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 13.0% / 33% | 8.8% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 92.4% / 33% | 62.5% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -87.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$37M |
| Free Cash Flow | -$37M |
| Total Debt | $15M |
| Debt-to-Equity | 887.0 |
| Current Ratio | 2.4 |
| Total Assets | $26M |
Price & Trading
| Last Close | $10.82 |
| 50-Day MA | $9.92 |
| 200-Day MA | $9.50 |
| Avg Volume | 132K |
| Beta | 1.7 |
|
52-Week Range
$4.60
| |
About Elicio Therapeutics, Inc. (ELTX)
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Elicio Therapeutics, Inc. (ELTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Elicio Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Elicio Therapeutics, Inc.'s debt ratio?
Elicio Therapeutics, Inc.'s debt ratio is 13.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 92.4%.
What are Elicio Therapeutics, Inc.'s key financial metrics?
Elicio Therapeutics, Inc. has a market capitalization of $192M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.